Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

N/AApproved For MarketingNCT01779518

Gilead Sciences

Overview

This is a single arm, open-label study which will be opened at specific clinical sites at the request of an investigator for the treatment of individual subjects for whom there are no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD) with RBV; pegylated interferon may be added at the discretion of the investigator.

Study Type

EXPANDED_ACCESS

Conditions

Post-transplant Hepatitis C

Interventions

SofosbuvirDRUG

RibavirinDRUG

Pegylated InterferonDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> or = 18 years * Previously undergone orthotopic liver transplant (OLT) at least 2 months prior to the planned start of dosing * Aggressive Hepatitis C infection (including fibrosing cholestatic hepatitis C) * Life expectancy of \< 12 months if the HCV is left untreated Exclusion Criteria: * History of clinically significant drug allergy to nucleoside/nucleotide analogs * Participation in a clinical study with an investigational drug or biologic within 1 month prior to anticipated dose administration, unless information is available to determine that there is no safety or drug-drug interaction risk to the subject * Unable or unwilling to follow the contraception requirements

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.